By Professor Masayuki Yoshida
Statins have been the first choice option to prevent cardiovascular disease (CVD). However, because of insufficient efficacy in certain groups of high risk patients, such as familial hypercholesterolemia (FH), considerable interest exists in the search for alternatives to lower LDL-cholesterol (LDL-C). Recent approvals of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and the associated evidence, will influence future treatment regimen of dyslipidemia.
This presentation provides an overview of recent developments in the area of LDL-C lowering agents, and comment on clinical impact and/or why this topic/research is important.
Presented at the 22nd Annual Meeting of the International Society of Cardiovascular Pharmacotherapy (ISCP), 24th-25th August 2017. Barcelona, Spain.